Literature DB >> 1604822

Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis.

D Schols1, R Pauwels, J Desmyter, E De Clercq.   

Abstract

Depending on the cell line used for virus propagation, human immunodeficiency virus (HIV) particles may possess class II MHC proteins, as demonstrated by FACS analysis. HLA-DR appeared in high amounts at the HIV envelope, if the virus was grown in HLA-DR+ cells, but was absent if the virus had been grown in HLA-DR- cells. No other cellular constituents, including HLA-DQ and HLA-DP, were detected in these virions. The presence of HLA-DR in the virion envelope itself in preparations used for diagnostic purposes may explain some of the false-positive results obtained in earlier serological tests for HIV infection. Possible implications of these virus-associated cellular antigens in the immunopathogenesis of AIDS should be considered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1604822     DOI: 10.1016/0042-6822(92)90719-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

2.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.

Authors:  Y Takeuchi; F L Cosset; P J Lachmann; H Okada; R A Weiss; M K Collins
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation.

Authors:  M T Esser; D R Graham; L V Coren; C M Trubey; J W Bess; L O Arthur; D E Ott; J D Lifson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Detection of the cellular membrane proteins on human T cell leukemia virus type I.

Authors:  H Akari; Y Goto; T Shinjo
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.